glp-1 agonists reduce inflammation The anti-inflammatory feature of glucagon-like peptide-1 and its based diabetes drugs—Therapeutic potential exploration in lung injury GLP-1 Drugs: For Multiple Chronic

GIP (glucose-dependent insulinotropic polypeptide) is a hormone that may complement the effects of GLP-1 receptor agonists

Sarcopenia, or the age-related progressive loss of muscle mass and strength, has serious implications and is becoming more prevalent

Research, including recent findings from the SELECT trial, indicates that GLP-1 agonists like semaglutide can significantly reduce the risk of major cardiovascular events, such as heart attacks and strokes, especially in individuals with obesity but without diabetes

27 Importantly, GLP-1 action is short-lived, with a half-life of just 12 minutes in the bloodstream under normal physiological conditions, after which it is broken down by the enzyme dipeptidyl peptidase IV (DPP-4), resulting in a loss of its biological activity

A 2016 meta-analysis of 78 studies confirmed this result, finding that GLP-1 receptor agonists significantly lowered blood sugar levels compared to placebo